ID   MAAL_CLOTT              Reviewed;         413 AA.
AC   Q05514;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   07-APR-2021, entry version 101.
DE   RecName: Full=Methylaspartate ammonia-lyase;
DE            Short=MAL;
DE            EC=4.3.1.2;
DE   AltName: Full=3-methylaspartase ammonia-lyase;
DE   AltName: Full=Beta-methylaspartase;
OS   Clostridium tetanomorphum.
OC   Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
OC   Clostridium.
OX   NCBI_TaxID=1553;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 1-26, FUNCTION,
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.
RC   STRAIN=ATCC 15920 / DSM 528 / NCIMB 11547 / H1;
RX   PubMed=1420191; DOI=10.1021/bi00159a015;
RA   Goda S.K., Minton N.P., Botting N.P., Gani D.;
RT   "Cloning, sequencing, and expression in Escherichia coli of the Clostridium
RT   tetanomorphum gene encoding beta-methylaspartase and characterization of
RT   the recombinant protein.";
RL   Biochemistry 31:10747-10756(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24, AND PROTEIN SEQUENCE OF 1-24.
RC   STRAIN=ATCC 15920 / DSM 528 / NCIMB 11547 / H1;
RX   PubMed=8454064; DOI=10.1016/0014-5793(93)80042-s;
RA   Brecht M., Kellermann J., Plueckthun A.;
RT   "Cloning and sequencing of glutamate mutase component E from Clostridium
RT   tetanomorphum.";
RL   FEBS Lett. 319:84-89(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-71.
RC   STRAIN=ATCC 15920 / DSM 528 / NCIMB 11547 / H1;
RX   PubMed=8428631; DOI=10.1016/0014-5793(93)81488-l;
RA   Holloway D.E., Marsh E.N.G.;
RT   "Cloning and sequencing of glutamate mutase component E from Clostridium
RT   tetanomorphum. Organization of the mut genes.";
RL   FEBS Lett. 317:44-48(1993).
RN   [4]
RP   PROTEIN SEQUENCE OF 1-15.
RC   STRAIN=ATCC 15920 / DSM 528 / NCIMB 11547 / H1;
RX   PubMed=1397267; DOI=10.1016/0014-5793(92)81321-c;
RA   Marsh E.N.G., Holloway D.E.;
RT   "Cloning and sequencing of glutamate mutase component S from Clostridium
RT   tetanomorphum. Homologies with other cobalamin-dependent enzymes.";
RL   FEBS Lett. 310:167-170(1992).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY
RP   REGULATION, SUBSTRATE SPECIFICITY, AND COFACTOR.
RC   STRAIN=ATCC 15920 / DSM 528 / NCIMB 11547 / H1;
RX   PubMed=13630903;
RA   Barker H.A., Smyth R.D., Wilson R.M., Weissbach H.;
RT   "The purification and properties of beta-methylaspartase.";
RL   J. Biol. Chem. 234:320-328(1959).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF
RP   HIS-194; GLN-329 AND LYS-331, SUBSTRATE SPECIFICITY, ACTIVE SITE, AND
RP   SUBUNIT.
RC   STRAIN=ATCC 15920 / DSM 528 / NCIMB 11547 / H1;
RX   PubMed=19670200; DOI=10.1002/cbic.200900311;
RA   Raj H., Weiner B., Veetil V.P., Reis C.R., Quax W.J., Janssen D.B.,
RA   Feringa B.L., Poelarends G.J.;
RT   "Alteration of the diastereoselectivity of 3-methylaspartate ammonia lyase
RT   by using structure-based mutagenesis.";
RL   ChemBioChem 10:2236-2245(2009).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH MAGNESIUM, ACTIVE
RP   SITE, COFACTOR, AND SUBUNIT.
RX   PubMed=11748244; DOI=10.1074/jbc.m111180200;
RA   Asuncion M., Blankenfeldt W., Barlow J.N., Gani D., Naismith J.H.;
RT   "The structure of 3-methylaspartase from Clostridium tetanomorphum
RT   functions via the common enolase chemical step.";
RL   J. Biol. Chem. 277:8306-8311(2002).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH SUBSTRATE ANALOGS
RP   AND MAGNESIUM, FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF GLN-73 AND
RP   LEU-384, COFACTOR, AND SUBUNIT.
RX   PubMed=22614383; DOI=10.1038/nchem.1338;
RA   Raj H., Szymanski W., de Villiers J., Rozeboom H.J., Veetil V.P.,
RA   Reis C.R., de Villiers M., Dekker F.J., de Wildeman S., Quax W.J.,
RA   Thunnissen A.M., Feringa B.L., Janssen D.B., Poelarends G.J.;
RT   "Engineering methylaspartate ammonia lyase for the asymmetric synthesis of
RT   unnatural amino acids.";
RL   Nat. Chem. 4:478-484(2012).
CC   -!- FUNCTION: Involved in the methylaspartate cycle. Catalyzes the
CC       formation of the alpha,beta-unsaturated bond by the reversible anti
CC       elimination of ammonia from L-threo-beta-methylaspartate (L-threo-
CC       (2S,3S)-3-methylaspartate) to give mesaconate. It can also use L-
CC       erythro-beta-methylaspartate (L-erythro-(2S,3R)-3-methylaspartate), L-
CC       aspartate, fumarate and ethylfumarate as substrates.
CC       {ECO:0000269|PubMed:13630903, ECO:0000269|PubMed:1420191,
CC       ECO:0000269|PubMed:19670200, ECO:0000269|PubMed:22614383}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2S,3S)-3-methyl-L-aspartate = mesaconate + NH4(+);
CC         Xref=Rhea:RHEA:12829, ChEBI:CHEBI:28938, ChEBI:CHEBI:36986,
CC         ChEBI:CHEBI:58724; EC=4.3.1.2; Evidence={ECO:0000269|PubMed:13630903,
CC         ECO:0000269|PubMed:1420191, ECO:0000269|PubMed:19670200,
CC         ECO:0000269|PubMed:22614383};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11748244, ECO:0000269|PubMed:13630903,
CC         ECO:0000269|PubMed:22614383};
CC   -!- ACTIVITY REGULATION: Inhibited by calcium ions.
CC       {ECO:0000269|PubMed:13630903}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.65 mM for L-threo-beta-methylaspartate (with 4 mM of KCl at pH
CC         9.76 and at 25 degrees Celsius) {ECO:0000269|PubMed:13630903,
CC         ECO:0000269|PubMed:1420191, ECO:0000269|PubMed:19670200};
CC         KM=0.67 mM for L-threo-beta-methylaspartate (with 50 mM of KCl at pH
CC         9 and at 30 degrees Celsius) {ECO:0000269|PubMed:13630903,
CC         ECO:0000269|PubMed:1420191, ECO:0000269|PubMed:19670200};
CC         KM=0.7 mM for mesaconate (with 20 mM of MgCl(2) at pH 9 and at 30
CC         degrees Celsius) {ECO:0000269|PubMed:13630903,
CC         ECO:0000269|PubMed:1420191, ECO:0000269|PubMed:19670200};
CC         KM=1 mM for L-threo-beta-methylaspartate (with 20 mM of MgCl(2) at pH
CC         9 and at 30 degrees Celsius) {ECO:0000269|PubMed:13630903,
CC         ECO:0000269|PubMed:1420191, ECO:0000269|PubMed:19670200};
CC         KM=2.3 mM for L-aspartate (with 4 mM of KCl at pH 9.76 and at 25
CC         degrees Celsius) {ECO:0000269|PubMed:13630903,
CC         ECO:0000269|PubMed:1420191, ECO:0000269|PubMed:19670200};
CC         KM=2.8 mM for L-threo-beta-methylaspartate (with 0.3 mM of KCl at pH
CC         9 and at 30 degrees Celsius) {ECO:0000269|PubMed:13630903,
CC         ECO:0000269|PubMed:1420191, ECO:0000269|PubMed:19670200};
CC         Vmax=2089 umol/min/mg enzyme with L-threo-beta-methylaspartate as
CC         substrate (with 50 mM of KCl at pH 9 and at 30 degrees Celsius)
CC         {ECO:0000269|PubMed:13630903, ECO:0000269|PubMed:1420191,
CC         ECO:0000269|PubMed:19670200};
CC         Vmax=309 umol/min/mg enzyme with L-threo-beta-methylaspartate as
CC         substrate (with 0.3 mM of KCl at pH 9 and at 30 degrees Celsius)
CC         {ECO:0000269|PubMed:13630903, ECO:0000269|PubMed:1420191,
CC         ECO:0000269|PubMed:19670200};
CC         Vmax=266 umol/min/mg enzyme with L-threo-beta-methylaspartate as
CC         substrate (with 4 mM of KCl at pH 9.76 and at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:13630903, ECO:0000269|PubMed:1420191,
CC         ECO:0000269|PubMed:19670200};
CC         Vmax=2.5 umol/min/mg enzyme with L-erythro-beta-methylaspartate as
CC         substrate (with 4 mM of KCl at pH 9.76 and at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:13630903, ECO:0000269|PubMed:1420191,
CC         ECO:0000269|PubMed:19670200};
CC         Vmax=2.4 umol/min/mg enzyme with L-aspartate as substrate (with 4 mM
CC         of KCl at pH 9.76 and at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:13630903, ECO:0000269|PubMed:1420191,
CC         ECO:0000269|PubMed:19670200};
CC         Note=Kcat is 61 sec(-1) for amination of mesaconate (with 20 mM of
CC         MgCl(2) at pH 9 and at 30 degrees Celsius). Kcat is 89 sec(-1) for
CC         deamination of L-threo-beta-methylaspartate (with 20 mM of MgCl(2) at
CC         pH 9 and at 30 degrees Celsius).;
CC       pH dependence:
CC         Optimum pH is 9.7. {ECO:0000269|PubMed:13630903,
CC         ECO:0000269|PubMed:1420191, ECO:0000269|PubMed:19670200};
CC       Temperature dependence:
CC         Optimum temperature is 55 degrees Celsius. It retains only half of
CC         its original activity after a 30 minutes incubation period at 50
CC         degrees Celsius. {ECO:0000269|PubMed:13630903,
CC         ECO:0000269|PubMed:1420191, ECO:0000269|PubMed:19670200};
CC   -!- PATHWAY: Amino-acid degradation; L-glutamate degradation via mesaconate
CC       pathway; acetate and pyruvate from L-glutamate: step 2/4.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:11748244,
CC       ECO:0000269|PubMed:1420191, ECO:0000269|PubMed:19670200,
CC       ECO:0000269|PubMed:22614383}.
CC   -!- SIMILARITY: Belongs to the methylaspartate ammonia-lyase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S48141; AAB24070.1; -; Genomic_DNA.
DR   EMBL; X70499; CAA49911.1; -; Genomic_DNA.
DR   EMBL; X70695; CAA50027.1; -; Genomic_DNA.
DR   PIR; B44285; B44285.
DR   PDB; 1KCZ; X-ray; 1.90 A; A/B=1-413.
DR   PDB; 1KD0; X-ray; 1.90 A; A/B=1-413.
DR   PDB; 3ZVH; X-ray; 1.99 A; A/B=1-413.
DR   PDB; 3ZVI; X-ray; 1.90 A; A/B=1-413.
DR   PDBsum; 1KCZ; -.
DR   PDBsum; 1KD0; -.
DR   PDBsum; 3ZVH; -.
DR   PDBsum; 3ZVI; -.
DR   SMR; Q05514; -.
DR   DrugBank; DB03661; L-cysteic acid.
DR   BioCyc; MetaCyc:MONOMER-1103; -.
DR   BRENDA; 4.3.1.2; 1527.
DR   UniPathway; UPA00561; UER00618.
DR   EvolutionaryTrace; Q05514; -.
DR   GO; GO:0031419; F:cobalamin binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0050096; F:methylaspartate ammonia-lyase activity; IEA:UniProtKB-EC.
DR   GO; GO:0019553; P:glutamate catabolic process via L-citramalate; IEA:UniProtKB-UniPathway.
DR   CDD; cd03314; MAL; 1.
DR   Gene3D; 3.20.20.120; -; 1.
DR   Gene3D; 3.30.390.10; -; 1.
DR   InterPro; IPR036849; Enolase-like_C_sf.
DR   InterPro; IPR029017; Enolase-like_N.
DR   InterPro; IPR006395; Me_Asp_am_lyase.
DR   InterPro; IPR022662; MeAsp_NH4-lyase_C.
DR   InterPro; IPR022665; MeAsp_NH4-lyase_N.
DR   Pfam; PF07476; MAAL_C; 1.
DR   Pfam; PF05034; MAAL_N; 1.
DR   PIRSF; PIRSF017107; MAL; 1.
DR   SFLD; SFLDF00007; methylaspartate_ammonia-lyase; 1.
DR   SUPFAM; SSF51604; SSF51604; 1.
DR   SUPFAM; SSF54826; SSF54826; 1.
DR   TIGRFAMs; TIGR01502; B_methylAsp_ase; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cobalamin; Cobalt; Direct protein sequencing; Lyase;
KW   Magnesium; Metal-binding.
FT   CHAIN           1..413
FT                   /note="Methylaspartate ammonia-lyase"
FT                   /id="PRO_0000084547"
FT   REGION          360..361
FT                   /note="L-threo-beta-methylaspartate binding"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        331
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000269|PubMed:11748244,
FT                   ECO:0000269|PubMed:19670200"
FT   METAL           238
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000269|PubMed:11748244,
FT                   ECO:0000269|PubMed:22614383"
FT   METAL           273
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000269|PubMed:11748244,
FT                   ECO:0000269|PubMed:22614383"
FT   METAL           307
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000269|PubMed:11748244,
FT                   ECO:0000269|PubMed:22614383"
FT   BINDING         172
FT                   /note="L-threo-beta-methylaspartate"
FT                   /evidence="ECO:0000250"
FT   BINDING         329
FT                   /note="L-threo-beta-methylaspartate"
FT   BINDING         361
FT                   /note="L-threo-beta-methylaspartate"
FT   SITE            194
FT                   /note="Transition state stabilizer"
FT   MUTAGEN         73
FT                   /note="Q->A: It has very broad nucleophile scope and
FT                   excellent regio- and diastereoselectivity in the amination
FT                   reaction. This mutation strongly moves the specificity of
FT                   MAL away from ammonia and towards methylamine. It is highly
FT                   enantioselective."
FT                   /evidence="ECO:0000269|PubMed:22614383"
FT   MUTAGEN         194
FT                   /note="H->A: Strong (160-fold) decrease of the catalytic
FT                   efficiency for deamination and slight (1.8-fold) decrease
FT                   of affinity binding for L-threo-beta-methylaspartate. 7-
FT                   fold decrease of the catalytic efficiency for amination and
FT                   20-fold decrease of affinity binding for mesaconate. It
FT                   does not show any major conformational changes."
FT                   /evidence="ECO:0000269|PubMed:19670200"
FT   MUTAGEN         194
FT                   /note="H->R: It abolishes deaminase and aminase activities
FT                   and does not show any major conformational changes."
FT                   /evidence="ECO:0000269|PubMed:19670200"
FT   MUTAGEN         329
FT                   /note="Q->A: Very strong decrease of the catalytic
FT                   efficiency for deamination, whereas the affinity binding
FT                   for L-threo-beta-methylaspartate is not affected. Strong
FT                   (240-fold) decrease of the catalytic efficiency for
FT                   amination and slight (2.4-fold) decrease of affinity
FT                   binding for mesaconate. It does not show any major
FT                   conformational changes."
FT                   /evidence="ECO:0000269|PubMed:19670200"
FT   MUTAGEN         329
FT                   /note="Q->R: It abolishes deaminase and aminase activities
FT                   and does not show any major conformational changes."
FT                   /evidence="ECO:0000269|PubMed:19670200"
FT   MUTAGEN         331
FT                   /note="K->A: It abolishes deaminase and aminase activities
FT                   and does not show any major conformational changes."
FT                   /evidence="ECO:0000269|PubMed:19670200"
FT   MUTAGEN         331
FT                   /note="K->G: It abolishes deaminase and aminase activities
FT                   and does not show any major conformational changes."
FT                   /evidence="ECO:0000269|PubMed:19670200"
FT   MUTAGEN         331
FT                   /note="K->H: It abolishes deaminase and aminase activities
FT                   and does not show any major conformational changes."
FT                   /evidence="ECO:0000269|PubMed:19670200"
FT   MUTAGEN         331
FT                   /note="K->Q: It abolishes deaminase and aminase activities
FT                   and does not show any major conformational changes."
FT                   /evidence="ECO:0000269|PubMed:19670200"
FT   MUTAGEN         331
FT                   /note="K->R: It abolishes deaminase and aminase activities
FT                   and does not show any major conformational changes."
FT                   /evidence="ECO:0000269|PubMed:19670200"
FT   MUTAGEN         384
FT                   /note="L->A: It has very broad electrophile scope and
FT                   excellent regio- and enantioselectivity in the amination
FT                   reaction."
FT                   /evidence="ECO:0000269|PubMed:22614383"
FT   STRAND          2..11
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          14..18
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           20..24
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          28..30
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          33..36
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          44..49
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          52..59
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          64..69
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   TURN            73..76
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           86..96
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           98..101
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           109..118
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           128..146
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           150..158
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           179..186
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          190..194
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           200..204
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           209..225
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          234..238
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           242..246
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   TURN            247..249
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           251..265
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          270..273
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           281..298
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          302..306
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           313..321
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          325..330
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           333..335
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           339..350
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          354..357
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           365..378
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          381..384
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   STRAND          387..391
FT                   /evidence="ECO:0007744|PDB:1KCZ"
FT   HELIX           392..410
FT                   /evidence="ECO:0007744|PDB:1KCZ"
SQ   SEQUENCE   413 AA;  45534 MW;  4451923DB035EF13 CRC64;
     MKIVDVLCTP GLTGFYFDDQ RAIKKGAGHD GFTYTGSTVT EGFTQVRQKG ESISVLLVLE
     DGQVAHGDCA AVQYSGAGGR DPLFLAKDFI PVIEKEIAPK LIGREITNFK PMAEEFDKMT
     VNGNRLHTAI RYGITQAILD AVAKTRKVTM AEVIRDEYNP GAEINAVPVF AQSGDDRYDN
     VDKMIIKEAD VLPHALINNV EEKLGLKGEK LLEYVKWLRD RIIKLRVRED YAPIFHIDVY
     GTIGAAFDVD IKAMADYIQT LAEAAKPFHL RIEGPMDVED RQKQMEAMRD LRAELDGRGV
     DAELVADEWC NTVEDVKFFT DNKAGHMVQI KTPDLGGVNN IADAIMYCKA NGMGAYCGGT
     CNETNRSAEV TTNIGMACGA RQVLAKPGMG VDEGMMIVKN EMNRVLALVG RRK
//
